Pfizer-Allergan Deal Faces Risk from U.S. Inversion Rules
(Bloomberg) As the U.S. took tougher steps Monday to limit the tax-cutting power of corporate inversions, analysts said the new rules may put a planned $160 billion merger between Pfizer Inc. and Allergan Plc in jeopardy. By Tuesday, Allergan shares were trading at $224.78 at 8:30 a.m. in New York, below their price of $271.57 […]